Searched for
KUNAL DHAMESHA
Stocks that may gain from Covid surgeNow, with the virus making a comeback, companies dealing in oxygen or medical equipment supplies, manufacturers of Covid-19 drugs, vaccine ...- Dispute settlement gives this stock an edge over peers in pharma packKunal Dhamesha of Emkay Global raised his price target for the stock to Rs 1,000 and sees potential gain of Rs 45 per share from the settle...
- API business helped Dr Reddy's beat revenue expectations: SystematixA lot of Dr Reddy’s revenue comes in dollars and hence the significant depreciation of Indian rupee against the US dollar impacted the gros...
- Why a new expat CEO may be good news for Dr Reddy’sDrug maker undergoing major changes under Erez Islraeli
- Brokerages raise Dr Reddy’s EPS estimate, but upside looks cappedAnalysts expect the acquisition to be funded through a bridge loan, with quick de-leveraging by FY22 through internal accruals.
- It is too premature to take a call on Aurobindo Pharma: Kunal Dhamesha, SBICAP SecuritiesThe injectables plant is important from their future growth as well as current revenue perspective.
Load More